Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence
Lung · 2023-08 · 201 (4) · 363-369
DOI: 10.1007/s00408-023-00632-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung, online erschienen am 04.07.2023. Verfasst von M Armati und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Surgery and Neurosciences, Respiratory Disease and Lung Transplant Unit, Siena University, 53100, Siena, Italy. Hauptthemen laut MEDLINE: Bronchiolitis Obliterans, Bronchiolitis Obliterans Syndrome, Lung Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Siena.
Abstract (Originalsprache)
Introduction
Bronchiolitis obliterans syndrome (BOS) is the most common form of CLAD and is characterized by airflow limitation and an obstructive spirometry pattern without parenchymal opacities. The protein signature of BOS lesions concerns extracellular matrix organization and aberrant basement membrane composition. In this pilot study, we investigated the presence of COL4A5 in the serum of patients with BOS.
Methods
41 patients who had undergone LTX were enrolled. Of these, 27 developed BOS and 14 (control group) were considered stable at the time of serum sampling. Of BOS patients, serum samples were analysed at the time of BOS diagnosis and before the clinical diagnosis (pre-BOS). COL4A5 levels were detected through the ELISA kit.
Results
Serum concentrations of COL4A5 were higher in pre-BOS than in stable patients (40.5 ± 13.9 and 24.8 ± 11.4, respectively, p = 0.048). This protein is not influenced by comorbidities, such as acute rejection or infections, or by therapies. Survival analysis also reveals that a higher level of COL4A5 was also associated with less probability of survival. Our data showed a correlation between concentrations of COL4A5 and FEV1 at the time of diagnosis of BOS.
Conclusion
Serum concentrations of COL4A5 can be considered a good prognostic marker due to their association with survival and correlation with functional parameters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Surgery and Neurosciences, Respiratory Disease and Lung Transplant Unit, Siena University, 53100, Siena, Italy.
- Unit of Respiratory Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100, Sassari, Italy.
- Department of Medical Sciences, Surgery and Neurosciences, Respiratory Disease and Lung Transplant Unit, Siena University, 53100, Siena, Italy. laurabergantini@gmail.com.
Förderung
- Università degli Studi di Siena
Zitieren
APA
Armati, M., Cattelan, S., Guerrieri, M., Messina, M., Perea, B., Genovese, M., d'Alessandro, M., Gangi, S., Cameli, P., Perillo, F., Bennett, D., Fossi, A., Tuscany Transplant Group, Bargagli, E., & Bergantini, L. (2023). Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence. Lung, 201(4), 363-369. https://doi.org/10.1007/s00408-023-00632-8
Vancouver
Armati M, Cattelan S, Guerrieri M, Messina M, Perea B, Genovese M, et al. Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence. Lung. 2023;201(4):363-369. doi:10.1007/s00408-023-00632-8
BibTeX
@article{Armati2023,
author = {Armati, M and Cattelan, S and Guerrieri, M and Messina, M and Perea, B and Genovese, M and d'Alessandro, M and Gangi, S and Cameli, P and Perillo, F and Bennett, D and Fossi, A and Tuscany Transplant Group, Tuscany Transplant Group and Bargagli, E and Bergantini, L},
title = {Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence},
journal = {Lung},
year = {2023},
volume = {201},
number = {4},
pages = {363--369},
doi = {10.1007/s00408-023-00632-8}
}
EUVIMED